It is clear that (1) Epidermal Growth Factor Receptor (EGFR) inhibitors could provide a beneficial clinical outcome for metastatic Colorectal Cancer (mCRC) patients with wild-type rat sarcoma viral oncogene homolog (RAS) genes rather than mutant types. Here, EGFR is linked to metastatic colorectal cancer.